(Senior) Medical Science Liaison - Heartland
TempusSalary not specified
- Full Time
- Senior (5 to 8 years)
Not SpecifiedCompensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Medical Affairs, HealthcareIndustries
Requirements
Candidates must hold a Doctor of Optometry (OD), Medical Degree (MD), Doctor of Pharmacy (PharmD), or PhD degree with demonstrated expertise in eye care. Preferred experience includes at least three years as a Medical Science Liaison in eye care, or three years of clinical experience in eyecare with at least one year of industry experience, or seven plus years of clinical practice in eyecare.
Responsibilities
The Medical Science Liaison will manage key opinion leader (KOL) optometrists and ophthalmologists in a designated region, ensuring compliant conduct, serve as the primary medical affairs KOL point of contact for scientific exchange, collect actionable insights to shape medical strategy, provide whole practice education to optometric and ophthalmic centers, provide resources for disease state education, instruct customers on investigator initiated trial and medical information procedures, identify and recommend KOLs for various projects, plan KOL engagements and attend scientific sessions, liaise with medical societies, present scientific evidence to the payer community, participate in continual optimization of training and processes, host local scientific exchanges, participate in compliant engagements with cross-functional teams, provide clinical trial support, and manage territory budget and CRM entries.
Skills
KOL Management
Medical Affairs
Scientific Exchange
Clinical Education
Payer Communication
Clinical Trial Support
CRM Management
Territory Management
Tarsus Pharamceuticals
Develops treatments for eye care diseases
About Tarsus Pharamceuticals
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company is also working on other potential treatments for conditions such as Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong pipeline of future products. Their goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.
Irvine, CaliforniaHeadquarters
2017Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees